VAXXA AB |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.725 SEK | -2.68% |
|
-3.97% | -34.09% |
| 04-10 | Vaxxa AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 02-23 | Vaxxa AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 25.12 | 15.51 | 4.701 | 9.691 | 23.69 | 12.98 |
| Enterprise Value (EV) 1 | 23.52 | 11.62 | 4.674 | 4.459 | 19 | 11.97 |
| P/E ratio | -5.9 x | -3.56 x | -0.94 x | -3.42 x | -1.95 x | -0.25 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 6.52 x | 5.33 x | 3.38 x | 16.1 x | 17.9 x | 0.28 x |
| EV / Revenue | 6.11 x | 3.99 x | 3.36 x | 7.42 x | 14.4 x | 0.26 x |
| EV / EBITDA | -5.65 x | -2.8 x | -0.95 x | -0.83 x | -2.51 x | -3.53 x |
| EV / FCF | -6.86 x | -6.95 x | -1.24 x | -1.52 x | -4.92 x | -0.74 x |
| FCF Yield | -14.6% | -14.4% | -80.7% | -65.8% | -20.3% | -134% |
| Price to Book | 8.38 x | 3.37 x | 3.6 x | 1.78 x | 2.28 x | 1.58 x |
| Nbr of stocks (in thousands) | 31.8 | 48.5 | 48.5 | 170 | 601 | 1,828 |
| Reference price 2 | 790.0 | 320.0 | 97.00 | 57.00 | 39.40 | 7.100 |
| Announcement Date | 4/25/18 | 4/29/19 | 4/23/20 | 4/10/21 | 3/30/22 | 5/10/23 |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net sales 1 | 3.852 | 2.913 | 1.393 | 0.6005 | 1.322 | 45.68 |
| EBITDA 1 | -4.162 | -4.159 | -4.908 | -5.387 | -7.57 | -3.391 |
| EBIT 1 | -4.242 | -4.249 | -5.013 | -5.465 | -7.894 | -14.14 |
| Operating Margin | -110.12% | -145.87% | -359.89% | -910.06% | -597.36% | -30.95% |
| Earnings before Tax (EBT) 1 | -4.248 | -4.344 | -5.017 | -5.594 | -12.7 | -50.87 |
| Net income 1 | -4.248 | -4.344 | -5.017 | -5.594 | -12.7 | -51.14 |
| Net margin | -110.28% | -149.15% | -360.21% | -931.54% | -961.03% | -111.96% |
| EPS 2 | -134.0 | -89.99 | -103.1 | -16.68 | -20.25 | -28.01 |
| Free Cash Flow 1 | -3.427 | -1.673 | -3.771 | -2.936 | -3.865 | -16.09 |
| FCF margin | -88.95% | -57.44% | -270.71% | -488.87% | -292.5% | -35.22% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 4/25/18 | 4/29/19 | 4/23/20 | 4/10/21 | 3/30/22 | 5/10/23 |
1SEK in Million2SEK
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 1.6 | 3.89 | 0.03 | 5.23 | 4.69 | 1.01 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -3.43 | -1.67 | -3.77 | -2.94 | -3.87 | -16.1 |
| ROE (net income / shareholders' equity) | -158% | -114% | -170% | -92% | -119% | -568% |
| ROA (Net income/ Total Assets) | -83.3% | -59.9% | -73.6% | -44.9% | -39.9% | -59.3% |
| Assets 1 | 5.099 | 7.256 | 6.814 | 12.45 | 31.82 | 86.18 |
| Book Value Per Share 2 | 94.30 | 95.00 | 26.90 | 31.90 | 17.30 | 4.480 |
| Cash Flow per Share 2 | 50.30 | 80.20 | 0.5700 | 15.40 | 7.800 | 2.240 |
| Capex 1 | 0.04 | 0.11 | - | 0.13 | - | 0.13 |
| Capex / Sales | 0.94% | 3.8% | - | 22.05% | - | 0.28% |
| Announcement Date | 4/25/18 | 4/29/19 | 4/23/20 | 4/10/21 | 3/30/22 | 5/10/23 |
1SEK in Million2SEK
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
- Stock Market
- Equities
- VAXXA Stock
- Financials Vaxxa AB
